FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2961330592> ?p ?o ?g. }

• W2961330592 endingPage "141" @default.
• W2961330592 startingPage "132" @default.
• W2961330592 abstract "Episodic cluster headache is a disabling neurologic disorder that is characterized by daily headache attacks that occur over periods of weeks or months. Galcanezumab, a humanized monoclonal antibody to calcitonin gene-related peptide, may be a preventive treatment for cluster headache.We enrolled patients who had at least one attack every other day, at least four total attacks, and no more than eight attacks per day during a baseline assessment, as well as a history of cluster headache periods lasting at least 6 weeks, and randomly assigned them to receive galcanezumab (at a dose of 300 mg) or placebo, administered subcutaneously at baseline and at 1 month. The primary end point was the mean change from baseline in the weekly frequency of cluster headache attacks across weeks 1 through 3 after receipt of the first dose. The key secondary end point was the percentage of patients who had a reduction from baseline of at least 50% in the weekly frequency of cluster headache attacks at week 3. Safety was also assessed.Recruitment was halted before the trial reached the planned sample size of 162 because too few volunteers met the eligibility criteria. Of 106 enrolled patients, 49 were randomly assigned to receive galcanezumab and 57 to receive placebo. The mean (±SD) number of cluster headache attacks per week in the baseline period was 17.8±10.1 in the galcanezumab group and 17.3±10.1 in the placebo group. The mean reduction in the weekly frequency of cluster headache attacks across weeks 1 through 3 was 8.7 attacks in the galcanezumab group, as compared with 5.2 in the placebo group (difference, 3.5 attacks per week; 95% confidence interval, 0.2 to 6.7; P = 0.04). The percentage of patients who had a reduction of at least 50% in headache frequency at week 3 was 71% in the galcanezumab group and 53% in the placebo group. There were no substantial between-group differences in the incidence of adverse events, except that 8% of the patients in the galcanezumab group had injection-site pain.Galcanezumab administered subcutaneously at a dose of 300 mg once monthly reduced the weekly frequency of attacks of episodic cluster headache across weeks 1 through 3 after the initial injection, as compared with placebo. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT02397473.)." @default.
• W2961330592 created "2019-07-23" @default.
• W2961330592 creator A5003359125 @default.
• W2961330592 creator A5018010521 @default.
• W2961330592 creator A5027240972 @default.
• W2961330592 creator A5030018731 @default.
• W2961330592 creator A5041938684 @default.
• W2961330592 creator A5050512906 @default.
• W2961330592 creator A5052388799 @default.
• W2961330592 creator A5054140183 @default.
• W2961330592 creator A5057290642 @default.
• W2961330592 creator A5058994427 @default.
• W2961330592 creator A5059017023 @default.
• W2961330592 creator A5062092404 @default.
• W2961330592 creator A5077286313 @default.
• W2961330592 date "2019-07-11" @default.
• W2961330592 modified "2023-10-14" @default.
• W2961330592 title "Trial of Galcanezumab in Prevention of Episodic Cluster Headache" @default.
• W2961330592 cites W1532754033 @default.
• W2961330592 cites W1545409067 @default.
• W2961330592 cites W1976768683 @default.
• W2961330592 cites W1985355940 @default.
• W2961330592 cites W1991191376 @default.
• W2961330592 cites W1996081907 @default.
• W2961330592 cites W2000366267 @default.
• W2961330592 cites W2019591295 @default.
• W2961330592 cites W2019729730 @default.
• W2961330592 cites W2026224594 @default.
• W2961330592 cites W2069874361 @default.
• W2961330592 cites W2072601405 @default.
• W2961330592 cites W2083821823 @default.
• W2961330592 cites W2088630102 @default.
• W2961330592 cites W2089857856 @default.
• W2961330592 cites W2091416449 @default.
• W2961330592 cites W2096003971 @default.
• W2961330592 cites W2103752861 @default.
• W2961330592 cites W2125635464 @default.
• W2961330592 cites W2127751874 @default.
• W2961330592 cites W2135310849 @default.
• W2961330592 cites W2136901194 @default.
• W2961330592 cites W2137787323 @default.
• W2961330592 cites W2138814983 @default.
• W2961330592 cites W2146909465 @default.
• W2961330592 cites W2148011499 @default.
• W2961330592 cites W2148083007 @default.
• W2961330592 cites W2151875733 @default.
• W2961330592 cites W2156947103 @default.
• W2961330592 cites W2317717259 @default.
• W2961330592 cites W2621779967 @default.
• W2961330592 cites W2768876632 @default.
• W2961330592 cites W2769724041 @default.
• W2961330592 cites W2780526171 @default.
• W2961330592 cites W2801085490 @default.
• W2961330592 cites W2801341258 @default.
• W2961330592 cites W2853108461 @default.
• W2961330592 cites W4232777839 @default.
• W2961330592 cites W4247904998 @default.
• W2961330592 doi "https://doi.org/10.1056/nejmoa1813440" @default.
• W2961330592 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31291515" @default.
• W2961330592 hasPublicationYear "2019" @default.
• W2961330592 type Work @default.
• W2961330592 sameAs 2961330592 @default.
• W2961330592 citedByCount "159" @default.
• W2961330592 countsByYear W29613305922019 @default.
• W2961330592 countsByYear W29613305922020 @default.
• W2961330592 countsByYear W29613305922021 @default.
• W2961330592 countsByYear W29613305922022 @default.
• W2961330592 countsByYear W29613305922023 @default.
• W2961330592 crossrefType "journal-article" @default.
• W2961330592 hasAuthorship W2961330592A5003359125 @default.
• W2961330592 hasAuthorship W2961330592A5018010521 @default.
• W2961330592 hasAuthorship W2961330592A5027240972 @default.
• W2961330592 hasAuthorship W2961330592A5030018731 @default.
• W2961330592 hasAuthorship W2961330592A5041938684 @default.
• W2961330592 hasAuthorship W2961330592A5050512906 @default.
• W2961330592 hasAuthorship W2961330592A5052388799 @default.
• W2961330592 hasAuthorship W2961330592A5054140183 @default.
• W2961330592 hasAuthorship W2961330592A5057290642 @default.
• W2961330592 hasAuthorship W2961330592A5058994427 @default.
• W2961330592 hasAuthorship W2961330592A5059017023 @default.
• W2961330592 hasAuthorship W2961330592A5062092404 @default.
• W2961330592 hasAuthorship W2961330592A5077286313 @default.
• W2961330592 hasBestOaLocation W29613305921 @default.
• W2961330592 hasConcept C126322002 @default.
• W2961330592 hasConcept C142724271 @default.
• W2961330592 hasConcept C164866538 @default.
• W2961330592 hasConcept C199360897 @default.
• W2961330592 hasConcept C203092338 @default.
• W2961330592 hasConcept C204787440 @default.
• W2961330592 hasConcept C27081682 @default.
• W2961330592 hasConcept C2777942821 @default.
• W2961330592 hasConcept C2778541695 @default.
• W2961330592 hasConcept C41008148 @default.
• W2961330592 hasConcept C42219234 @default.
• W2961330592 hasConcept C535046627 @default.
• W2961330592 hasConcept C71924100 @default.
• W2961330592 hasConceptScore W2961330592C126322002 @default.
• W2961330592 hasConceptScore W2961330592C142724271 @default.

• next